AI Is Boosting Pharma Profits. Here’s Our 8.8% Dividend Play
Brett Owens, Chief Investment StrategistUpdated: March 3, 2026
Wall Street is mired in another panic over AI. And we contrarians are here for it.
Our play? As always, we’re going where first-level investors aren’t, quietly snapping up dividends AI is set to supercharge.
I’m talking specifically about an overlooked opportunity in drug stocks, which are about to see the value of their R&D dollars get a big boost from AI. We’re going to tap in with an 8.8%-yielding closed-end fund (CEF) that’s trading for 11.4% below its “true” value.
That discount exists in part because investors—worried about how AI may disrupt sectors like software—are ignoring pharma, and the accelerated product cycles (and cash flows!)… Read more

